---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-052893"
form_type: "8-K"
ticker: "RFL"
cik: "0001713863"
company_name: "Rafael Holdings, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:21:46.106243+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rafael Holdings Q3 net loss $32.4M ($1.36/sh) vs $1.4M loss YoY; driven by $89.9M IPR&D expense

## Summary
- Net loss from continuing operations of $32.4M ($1.36 diluted EPS) compared to $1.4M ($0.06) in prior-year quarter.
- Q3 includes $89.9M in-process R&D expense from Cornerstone acquisition treatment, offset by $31.3M recovery of Cornerstone receivables.
- Cash and marketable securities $72.4M as of April 30, 2024.
- Increased Day Three Labs stake to 79% majority, began consolidating Jan 2024; Q3 R&D up to $1.5M from $0.7M.
- Cyclo Therapeutics investment recorded $4.4M unrealized loss in Q3.

## SEC filing metadata
- accession: 0001213900-24-052893
- form_type: 8-K
- ticker: RFL
- cik: 0001713863
- company_name: Rafael Holdings, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1713863/000121390024052893/0001213900-24-052893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1713863/000121390024052893/ea0207870-8k_rafael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-052893
- JSON: https://secwatch.observer/filing/0001213900-24-052893.json
- Plain text: https://secwatch.observer/filing/0001213900-24-052893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.